207 related articles for article (PubMed ID: 34931674)
1. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
[TBL] [Abstract][Full Text] [Related]
2. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
Liao H; Zhang H; Shao J; Li X; Zheng WV; Li L; Yu G; Si L; Zhou T; Yao Z; Dai J; Xu D; Cheng G; Qu J; Liu Y; Chen J; Lu F
J Med Virol; 2023 Mar; 95(3):e28612. PubMed ID: 36840474
[TBL] [Abstract][Full Text] [Related]
5. Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.
Wu L; Yang Z; Zheng M
J Viral Hepat; 2024 May; 31(5):255-265. PubMed ID: 38332479
[TBL] [Abstract][Full Text] [Related]
6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
7. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
9. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
11. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
[TBL] [Abstract][Full Text] [Related]
12. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
13. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
15. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
16. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
17. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
19. Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era.
Nishikawa H; Kim SK; Asai A
In Vivo; 2024; 38(1):40-47. PubMed ID: 38148074
[TBL] [Abstract][Full Text] [Related]
20. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
